Stowers Institute for Medical Research

University of Kansas

University of Connecticut

Institute for Systems Biology

The Childrens' Mercy Hospital

Xi C He

Linheng Li

John M Perry

Leroy E Hood

Weiguo Andy Tao

Anuradha Roy

Qiang Tian

Tong Yin

Scott J Weir

Rajeswari Kasi

Xiuling Lu

Gurusingham Sitta Sittampalam

Aparna Venkatraman

Fang Tao

Tara Lin

The present disclosure provides, inter alia, methods for treating cancers including leukemia using low doses of an anthracycline such as doxorubicin.

Methods for overcoming WNT/beta-catenin anti-cancer resistance in leukemia stem cells

The disclosure provides methods of treating cancer by selectively inhibiting p-S-&#x3b2;-catenin, p-T-&#x3b2;-catenin, p-T-&#x3b2;-catenin, and/or p-S-&#x3b2;-catenin production and/or activity. Such methods also and/or limit cancer-initiating cells.

Methods for treating chemoresistant cancer-initiating cells

Methods and kits for expanding a stem cell population, particularly a hematopoietic stem cell population, in the presence of a DNA methyltransferase modulator and a Wnt pathway modulator are disclosed.

Methods, kits, and compositions for stem cell self-renewal

The present invention relates to a purified molecules, including antibodies, that bind specifically to murine &#x3b2;-catenin phosphorylated at amino acid position Serineand to orthologs thereof, such as mammalian orthologs, including human orthologs. Methods of making and using such purified molecules are also provided. Kits containing such purified molecules are further provided.

Method of detecting phosphorylation state of beta-catenin

Antibodies that bind specifically to phosphorylated &#x3b2;-catenin

Growing community of inventors

Kansas City, MO, United States of America

Xi C He